Compare NXL & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXL | ICCM |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.3M |
| IPO Year | 2022 | 2013 |
| Metric | NXL | ICCM |
|---|---|---|
| Price | $6.73 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | ★ 139.6K | 95.7K |
| Earning Date | 05-11-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $301,647.00 | N/A |
| Revenue This Year | $15.52 | $139.51 |
| Revenue Next Year | $100.00 | $75.66 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 78.78 | N/A |
| 52 Week Low | $0.22 | $0.13 |
| 52 Week High | $7.69 | $9.54 |
| Indicator | NXL | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 96.86 | 35.27 |
| Support Level | $0.44 | $2.15 |
| Resistance Level | N/A | $3.59 |
| Average True Range (ATR) | 0.18 | 0.21 |
| MACD | 0.69 | -0.02 |
| Stochastic Oscillator | 92.77 | 8.82 |
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.